レンツ・セラピューティクス
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.02 | $5M | -$39M |
| 2026 Q1 | -1.32 | $2M | -$34M |
| 2025 Q4 | -1.16 | $2M | -$33M |
| 2025 Q3 | -0.59 | $13M | -$9M |
| 2025 Q2 | -0.53 | $5M | -$12M |
| 2025 Q1 | -0.53 | $0 | -$16M |
| 2024 Q4 |
| -0.46 |
| $0 |
| -$9M |
| 2024 Q3 | -0.38 | $0 | -$11M |